ArticleJournal of natural medicines2026
Antioxidative Japanese herbal medicine formula prevents diabetic renal complications.
Article in Journal of natural medicines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes is the leading cause of chronic kidney disease. Hyperglycaemia in diabetes promotes the generation of reactive oxygen species, leading to diabetic complications. Although numerous antioxidant agents have been tested, none are currently recommended for the prevention of diabetic nephropathy. The Kampo formula Tsudosan, a traditional Japanese herbal medicine, possesses potent antioxidant properties. Therefore, its efficacy against diabetic nephropathy was investigated in diabetic Wistar rats. Vitamin E served as a conventional antioxidant, and dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, as a representative antiglycaemic. After 25 weeks of continuous drug administration, renal biomarkers and glomerular structural changes were assessed. At week 25, proteinuria was significantly ameliorated in the Tsudosan, dapagliflozin, vitamin E, and Saireito groups. Glomerular filtration rate was significantly lower in the dapagliflozin and diabetic control groups. The glomerular staining area for 8-hydroxy-2'-deoxyguanosine, a marker of oxidative stress, was significantly reduced in the Tsudosan group, to a level comparable with controls. Urinary concentrations of liver-type fatty acid-binding protein, a marker of tubular injury, were significantly reduced in the Tsudosan and vitamin E groups. The overlapping area ratios of podocin and CD2AP staining in the glomeruli were significantly greater in all the drug-treated and control groups than those in the diabetic group. In conclusion, the antioxidative Kampo formula, Tsudosan, demonstrated efficacy in preventing diabetic nephropathy in rats, showing superior performance compared with that of vitamin E. Specifically, Tsudosan may be most beneficial when administered in the early stages of diabetes.
Indexed as
Identifiers
41735618What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.